[1]郑玉民,颜珏.放射性核素显像在甲状旁腺功能亢进症中的应用[J].国际放射医学核医学杂志,2011,35(3):170-175.[doi:10.3760/cma.j.issn.1673-4114.2011.03.009]
 ZHENG Yu-min,YAN Jue.Application of radionuclide imaging in hyperparathyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):170-175.[doi:10.3760/cma.j.issn.1673-4114.2011.03.009]
点击复制

放射性核素显像在甲状旁腺功能亢进症中的应用(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第3期
页码:
170-175
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Application of radionuclide imaging in hyperparathyroidism
作者:
郑玉民 颜珏
卫生部中日友好医院核医学科, 北京 100029
Author(s):
ZHENG Yu-min YAN Jue
Department of Nuclear Medicine, China-Japan Friendship Hospital, Beijing 100029, China
关键词:
甲状旁腺功能亢进症放射性核素显像
Keywords:
HyperparathyroidismRadionuclide imaging
DOI:
10.3760/cma.j.issn.1673-4114.2011.03.009
摘要:
甲状旁腺功能亢进症(HPT)是由于甲状旁腺本身病变或继发于各种原因所致甲状旁腺激素分泌过多的一类内分泌疾病,其主要根据病史和生化检查来确诊,目前最有效的治疗方法是外科手术切除亢进的甲状旁腺组织或腺瘤,可用于术前定位诊断的影像学方法主要有放射性核素显像、超声、CT、MRI等。该文主要针对HPT放射性核素显像进行综述。
Abstract:
Hyperparathyroidism (HPT) is overactivity of the parathyroid glands resulting in excess production of parathyroid hormone.Excessive parathyroid hormone secretion may be due to problems in the glands themselves,or may be secondary HPT.The diagnosis is mainly based on the patient’s medical history and biochemical tests.The best treatment nowadays is surgical removal of the overactive parathyroid glands or adenoma.The imaging methods for the preoperative localization diagnosis include radionuclide imaging,ultrasonography,CT,MRI,etc.This article was a summary of HPT radionuclide imaging.

参考文献/References:

[1] Fedin G,Borsato N,Camerani M,et al.New perspectives in localizing enlarged parathyroids by technetium-thallium subtraction scan.J Nucl Med,1983,24(5):438-441.
[2] Basso LV,Keeling C,Goiis ML.Parathyroid imaging.Use of dual isotope scintigraphy for the localization of adenoma before surgery.Clin Nucl Med,1992,17(5):380-383.
[3] Hauty M,Swartz K,McClung M,et al.Technetium-thallium scintiscanning for localization of parathyroid adenomas and hyperplasia.A reappraisal.Am J Surg,1987,153(5):479-486.
[4] Coakley AJ,Kettle AG,Wells CP,et al.99mTc-sestamibi-a new agent for parathyroid imaging.Nucl Med Commun,1989,10(11):791-794.
[5] Melloul M,Paz A,Koren R,et al.99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to tumour size and oxyphil cell abundance.EurJ Nuci Med,2001,28(2):209-213.
[6] Tomas MB,Pugliese PV,Tronco GG,et al.Pinhole versus parallelhole collimators for parathyroid imaging:an intraindividual comparison.J Nucl Med Technol,2008,36(4):189-194.
[7] De Feo ML,Colagrande S,Biagini C,et al.Parathyroid glands combination of 99mTc-MIBI scintigraphy and US for demonstration of parathyroid glands and nodules.Radiology,2000,214(2):393-402.
[8] Hindié E,Mellière D,Jeanguillaume C,et al.Parathyroid imaging using simultaneous double-window recording of technetium-99m-sestamibi and iodine-123.J Nucl Med,1998,39(6):1100-1105.
[9] Chen CC,Holder LE,Scovill WA,et al.Comparison of parathyroid imaging with technetium-99m-pertechnetate/sestamibi subtraction,double-phase technetium-99m-sestamibi and technetium-99m-sestamibi SPECT.J Nucl Med,1997,38(6):834-839.
[10] Palestro CJ,Tomas MB,Tronco GG.Radionuclide imaging of the parathyroid glands.Semin Nucl Med,2005,35(4):266-276.
[11] Billotey C,Sarfati E,Aurengo A,et al.Advantages of SPECT in technetium-99m-sestamibi parathyroid scintigraphy.J Nucl Med,1996,37(11):1773-1778.
[12] Gayed IW,Kim EE,Broussard WF,et al.The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of parathyroid adenomas or hyperplasia.J Nucl Med,2005,46(2):248-252.
[13] Neumann DR,Obuchowski NA,Difilippe FP.Preoperative 123I/99mTcc-sostamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism.J Nucl Med,2008,49(12):2012-2017.
[14] Ishibashi M,Nishida H,Kumabe T,et al.Tc-99m tetrofosmin.A new diagnostic tracer for parathyroid imaging.Clin Nucl Med,1995,20(10):902-905.
[15] Hiromatsu Y,Ishibashi M,Nishida H,et al.Technetium-99m tetrofosmin parathyroid imaging in patients with primary hyperparathyroidism.Intern Med,2000,39(2):101-106.
[16] Fjeld JG,Erichsen K,Pfeffer PF,et al.Technetium-99m-tetrofosmain for parathyroid scintigraphy:a comparison with sestamibi.J Nucl Med,1997,38(6):831-834.
[17] Sundin A,Johansson C,Hellman P,et al.PET and parathyroid L-[carbon-11] methionine accumulation in hyperparathyroidism.J Nucl Med,1996,37(11):1766-1770.
[18] Beggs AD,Hain SF.Localization of parathyroid adenomas of using 11C-methionine positron emission tomography.Nucl Med Commun,2005,26(2):133-136.
[19] Otto D,Boemer AR,Hofmann M,et al.Pre-operative localization of hyperfunctional parathyroid tissue with 11C-methionine PET.Eur J Nucl Med Mol Imaging,2004,31(10):1405-1412.
[20] Weber T,Cammerer G,Schick C,et al.C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism.Horm Metab Res,2010,42(3):209-214.
[21] Bahar G,Feinmesser R,Joshua BZ,et al.Hyperfunctioning intrathyroid parathyroid gland:a potential cause of failure in parathy-roidectomy.Surgery,2006,139(6):821-826.
[22] Piga M,Bolasco P,Satta L,et al.Double phase parathyroid technetium-99m-MIBI scintigraphy to identify functional autonomy in secondary hyperparathyroidism.J Nucl Med,1996,37(4):565-569.
[23] Takeuchi H,Greep NC,Hoon DS,et al.Hypormethylation of adeno-sine triphosphate-binding cassette transporter genes in primaryhyperparathyroidism and its effect on sestamibi imaging.J ClinEndocrinol Metab,2007,92(5):1785-1790.
[24] Nichols KJ,Tonas MB,Tronco GG,et al.Preoperative parathyroid scintigraphic lesion localization:accuracy of various types of readings.Radiology,2008,248(1):221-232.
[25] Mihai R,Gleeson F,Buley ID,et al.Negative imaging studies for primary hyperparathyroidism are unavoidable:correlation of sestamibi and high-resolution ultrasound scanning with histological analysis in 150 patients.World J Surg,2006,30(5):697-704.
[26] Torregrosa JV,Fernández-Cruz L,Canalejo A,et al.99mTc-sostamibi scintigraphy and cell cycle in parathyroid glands of secondary hyperparathyroidism.World J Surg,2000,24(11):1386-1390.
[27] Kao A,Shiau YC,Tsai SC,et al.Technetium-99m methoxyisobutilisonitrile imaging for parathyroid adenoma:relationship to P-glycoprotein or multidrug resistance-related protein expression.Eur J Nucl Med Mol Imaging,2002,29(8):1012-1015.
[28] Yamaguchi S,Yachiku S,Hashimoto H,et al.Relation between technetium-99m methoxyisobutylisonitrile accumulation and multidrug resistance protein in the parathyroid glands.World J Surg,2002,26(1):29-34.
[29] Shiau YC,Tsai SC,Wang JJ,et al.Detecting parathyroid adenoma using technetium-99m tetrofosimin:comparison with P-glycoprotein and multidrug resistance related protein expression-a preliminary report.Nucl Med Biol,2002,29(3):339-344.
[30] Huang WT.Size and P-glycoprotein expression limit 99mTc-tetrofosmin uptake in parathyroid adenomas.Nucl Med Commun,2002,23(10):1001-1004.
[31] Fuster D,Ybarra J,Torregrosa JV,et al.Double-phase parathyroid 99mTc-sestamibi scintigraphy in chronic haemodialysis patients:correlation with biochemical markers of parathyroid function.Nucl Med Commun,2003,24(1):85-90.

相似文献/References:

[1]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
 Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[2]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
 Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
 Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]孙芳芳,张欣.uPAR放射性核素靶向显像研究进展[J].国际放射医学核医学杂志,2016,40(3):230.[doi:10.3760/cma.j.issn.1673-4114.2016.03.013]
 Sun Fangfang,Zhang Xin.Research progress of uPAR-targeted nuclear imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):230.[doi:10.3760/cma.j.issn.1673-4114.2016.03.013]
[5]安淑娴,宋少莉,黄钢.放射性核素标记的凋亡显像剂的研究进展[J].国际放射医学核医学杂志,2015,39(6):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
 An Shuxian,Song Shaoli,Huang Gang.Recent advances in apoptosis imaging using radionuclide-labeled tracers[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
[6]成钊汀,朱小华.99Tcm-MIBI显像在甲状旁腺功能亢进症中的应用及进展[J].国际放射医学核医学杂志,2015,39(1):37.[doi:10.3760/cma.j.issn.1673-4114.2015.01.009]
 Cheng Zhaoting,Zhu Xiaohua.Application and progress of 99Tcm-MIBI scintieraphy in parathyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):37.[doi:10.3760/cma.j.issn.1673-4114.2015.01.009]
[7]黄建敏,解朋,刘晓梅,等.以整合素αvβ3为靶点的肿瘤分子显像及靶向治疗[J].国际放射医学核医学杂志,2015,39(3):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
 Huang Jianmin,Xie Peng,Liu Xiaomei,et al.Integrins αvβ3 in molecular imaging and targeted therapy of neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
[8]郭宵峰,刘建中,孙琦婷.肺通气/灌注平面显像与肺灌注SPECT/CT对肺栓塞诊断价值的对比性研究[J].国际放射医学核医学杂志,2015,39(4):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
 Guo Xiaofeng,Liu Jianzhong,Sun Qiting.Comparative study of pulmonary ventilation/perfusion planar imaging and pulmonary perfusion SPECT combined with low-dose CT in the diagnosis of pulmonary embolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
[9]马春旭,袁卫红.甲状腺结节影像学诊断研究进展[J].国际放射医学核医学杂志,2014,38(1):48.[doi:10.3760/cma.j.issn 1673-4114.2014.01.010]
 Ma Chunxu,Yuan Weihong.Advanced research on imaging diagnosis of thyroid nodule[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):48.[doi:10.3760/cma.j.issn 1673-4114.2014.01.010]
[10]吕靖,张一帆.核素分子显像监测胚胎干细胞及诱导性多潜能干细胞移植的研究进展[J].国际放射医学核医学杂志,2014,38(2):106.[doi:10.3760/cma.j.issn.1673-4114.2014.02.009]
 Lyu Jing,Zhang Yifan.Advances in radionuclide imaging of monitoring embryonic stem cells and induced pluripotent stem cells transplantation[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):106.[doi:10.3760/cma.j.issn.1673-4114.2014.02.009]
[11]曹景佳,李亚明.SPECT/CT双时相联合减影技术诊断甲状旁腺功能亢进症的增益价值[J].国际放射医学核医学杂志,2018,(3):201.[doi:10.3760/cma.j.issn.1673-4114.2018.03.002]
 Cao Jingjia,Li Yaming.Incremental value of SPECT/CT fusion imaging with dual-phase and dual-tracer technique in the diagnostic localization of parathyroid lesions in patients with hyperparathyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(3):201.[doi:10.3760/cma.j.issn.1673-4114.2018.03.002]

备注/Memo

备注/Memo:
收稿日期:2011-02-28。
通讯作者:颜珏(Email:yanjue@i63.com)
更新日期/Last Update: 1900-01-01